Journal article
Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.
Abstract
Combination antithrombotic therapy with heparin plus aspirin decreases the risk of recurrent ischemic events in patients with acute coronary syndromes without persistent ST-segment elevation. Compared with standard unfractionated heparin, low-molecular-weight heparin (LMWH) has a more predictable antithrombotic effect, is easier to administer, and does not require coagulation monitoring. At 176 hospitals in 3 continents, 3,171 patients with …
Authors
Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J
Journal
Am J Cardiol, Vol. 82, No. 5B, pp. 19L–24L
Publication Date
September 10, 1998
DOI
10.1016/s0002-9149(98)00108-8
ISSN
0002-9149
Associated Experts
Medical Subject Headings (MeSH)
AdolescentAdultAgedAnticoagulantsAspirinDouble-Blind MethodDrug Administration RoutesDrug Therapy, CombinationElectrocardiographyEnoxaparinFemaleFollow-Up StudiesHeparin, Low-Molecular-WeightHumansMaleMiddle AgedMyocardial IschemiaPlatelet Aggregation InhibitorsProspective StudiesRecurrenceSafetySurvival RateTreatment Outcome